Onychomycosis Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Rising Prevalence of Onychomycosis
   3. Market Restraints
      1. Limited Treatment Efficacy
      2. Long Treatment Duration
   4. Market Opportunities
      1. Rising R&D Activities
   5. Market Trends
      1. Increasing Preference for Combination Therapies
      2. Adoption of Patient-Centric Approaches
5. MARKET SEGMENTATION
   1. By Types
      1. Proximal Subungual
      2. Distal Subungual
      3. Candidal
      4. White Superficial
      5. Total Dystrophic
   2. By Drugs
      1. Griseofulvin
      2. Ketoconazole
      3. Ciclopirox
      4. Terbinafine
      5. Others
   3. By Treatment
      1. Medication
      2. Topical Therapy
      3. Debridement
   4. By Route of Administration
      1. Oral
      2. Topical
      3. Others
   5. By Distribution Channel
      1. Direct
      2. Online Pharmacy
      3. Retailers
      4. Others
   6. By End Users
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
   7. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. AbbVie Inc.
      2. Amgen Inc.
      3. Allergan
      4. AstraZeneca
      5. Bristol-Myers Squibb Company
      6. Bausch Health Companies Inc.
      7. Bayer AG
      8. Eli Lilly and Company
      9. F. Hoffmann-La Roche Ltd
      10. GALDERMA
      11. GlaxoSmithKline plc
      12. Johnson & Johnson Services, Inc.
      13. Lupin Pharmaceuticals, Inc.
      14. Moberg Pharma AB
      15. Merck & Co., Inc.
      16. Novartis AG
      17. Pfizer Inc.
      18. Sanofi
      19. Teva Pharmaceutical Industries Ltd.
      20. Takeda Pharmaceutical Company Limited
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Onychomycosismarket?

The global market of Onychomycosis is projected to reach USD 5.35 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Onychomycosismarket?

The global Onychomycosis market has an estimated annual growth rate of 4.1%.

Q.3. What are the recent trends of Onychomycosismarket?

Increasing preference for combination therapies and adoption of patient-centric approaches are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Onychomycosis?

The major companies profiled in this report include AbbVie Inc., Amgen Inc., Allergan, AstraZeneca, Bristol-Myers Squibb Company, Bausch Health Companies Inc., Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GALDERMA, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Lupin Pharmaceuticals, Inc., Moberg Pharma AB, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, among others.

Q.5. Which region is estimated to held highest CAGR inOnychomycosismarket?

North America is estimated to hold biggest share in the market for Onychomycosis.